Adjuvant Osimertinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have completely reinvented therapeutic care for patients with metastatic non–small-cell lung cancer (NSCLC) harboring an activating EGFR mutation ( Ex19del or L858R ). The survival benefit with the third-generation EGFR-TKI osimertinib as compared with the first-generation agents gefitinib and erlotinib 1 has cemented its role in the current therapeutic landscape in patients with metastatic disease. However, no such advances have been seen over the past two decades for localized resectable disease. After complete resection, a small but significant survival benefit (5% at 5 years, corresponding to an 11% reduction in the risk of death) . . .